Online inquiry

IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7564MR)

This product GTTS-WQ7564MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets GPC3 gene. The antibody can be applied in Hepatocellular carcinoma (HCC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001164617.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2719
UniProt ID P51654
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ7564MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4912MR IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA C11D5.3 scFv-8A-F9Z CAR
GTTS-WQ15216MR IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA TACI-Fc
GTTS-WQ2828MR IVTScrip™ mRNA-Anti-NGF, AMG-403(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG-403
GTTS-WQ5561MR IVTScrip™ mRNA-Anti-CD33, CDP-771(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CDP-771
GTTS-WQ2571MR IVTScrip™ mRNA-Anti-IGF1R, AMG 479(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG 479
GTTS-WQ10985MR IVTScrip™ mRNA-Anti-CD79B, MCDS0593A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MCDS0593A
GTTS-WQ14075MR IVTScrip™ mRNA-Anti-DLL4, REGN-421(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-421
GTTS-WQ7809MR IVTScrip™ mRNA-Anti-env, GS-HIV(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GS-HIV
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW